FDA approves Johnson & Johnson’s nasal spray for depression as standalone treatment – CNBC

Spravato is now the first-ever standalone therapy for treatment-resistant depression, and is on its way to becoming a blockbuster product.

#stockmarket #breaking

Leave a Reply

WP Twitter Auto Publish Powered By : XYZScripts.com